NCT06561347 - Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Zanubrutinib

A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor

DRUG

Bendamustine

Alkylating agent

DRUG

Rituximab

Monoclonal antibody

Trial Locations (3)

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute, Boston